Compare YHC & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHC | NXTS |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Agricultural Chemicals |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 2.4M |
| IPO Year | 2023 | 2021 |
| Metric | YHC | NXTS |
|---|---|---|
| Price | $1.33 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 40.4K | 17.6K |
| Earning Date | 04-15-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 8.28 | N/A |
| Revenue | ★ $1,120,622.00 | $263,445.00 |
| Revenue This Year | $1,267.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.16 | ★ N/A |
| Revenue Growth | ★ 86.42 | N/A |
| 52 Week Low | $0.02 | $0.55 |
| 52 Week High | $2.72 | $23.80 |
| Indicator | YHC | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 29.08 |
| Support Level | $1.27 | $0.55 |
| Resistance Level | $2.20 | $2.08 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 24.00 | 13.84 |
LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.